Corporate Profile
Proteon Therapeutics is a biopharmaceutical company developing vonapanitase (formerly PRT-201), an investigational drug to improve arteriovenous fistula (AVF) patency, the period of time during which an AVF remains open with adequate blood flow to enable hemodialysis. Vonapanitase is being evaluated in two Phase 3 clinical trials, and data from the first Phase 3 clinical trial is anticipated in December 2016. Vonapanitase may have multiple surgical and endovascular applications in which vessel injury leads to blockages in blood vessels and reduced blood flow, and is also currently being investigated as a potential treatment for patients with symptomatic peripheral artery disease (PAD). The company is headquartered in Waltham, MA.
Stock Quote
PRTO (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%)0.00 (0.00%)
Data as of 10/21/16 3:53 p.m. ET
Refresh quote
Recent Press ReleasesMore >>
10/20/16Proteon Therapeutics Appoints Paul Hastings Chairman of Its Board of DirectorsPrinter Friendly Version
09/01/16Proteon Therapeutics to Present at Two Upcoming Investor ConferencesPrinter Friendly Version
08/08/16Proteon Therapeutics Announces Second Quarter 2016 Financial ResultsPrinter Friendly Version
06/15/16Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 22ndPrinter Friendly Version
Upcoming EventsMore >>
11/16/16 8:00 a.m. ET
Stifel 2016 Healthcare Conference
Oppenheimer Life Science Summit
Print Page Print Page
E-mail Page E-mail Page
RSS Feeds RSS Feeds
E-mail Alerts E-mail Alerts
Financial Tear Sheet Financial Tear Sheet

IR Contact

George Eldridge
781-890-0102 x1026

Media Contact

Daniel Gottlieb
781-890-0102 x1025